Company profile: Vascular Perfusion Solutions
1.1 - Company Overview
Company description
- Provider of medical devices to preserve and resuscitate vascularized organs, notably the VP.S ENCORE hypothermic machine perfusion system that extends organ viability for transplantation using a nutrient-rich solution instead of ice. Compact and carry-on sized, it includes a single-use component, operates in various environments, and enables reliable organ transport by ground or aircraft without special vehicles.
Products and services
- Ease of Use: A single-use component streamlines operation across varied environments, architected for simplicity and reliability during organ transport
- Portable: The carry-on-sized system is designed for easy transportation, facilitating organ movement by ground or aircraft without the need for special vehicles
- VP.S ENCORE®: A hypothermic machine perfusion device that extends organ viability outside the body for transplantation by circulating a nutrient-rich solution instead of conventional ice cooling
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Vascular Perfusion Solutions
Lifeline Scientific
HQ: United States
Website
- Description: Provider of medical technology products and services for cell, tissue, and organ transplantation in the U.S. and internationally, including the LifePort Kidney Transporter for kidney preservation, evaluation, and transport, the LifePort Liver Transporter, and T3 (Tissue Testing Technologies), a cryobiology lab developing preservation and transport methods for transplantation and other biomedical applications.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Lifeline Scientific company profile →
OrganOx
HQ: United Kingdom
Website
- Description: Provider of normothermic machine perfusion technology for donor livers via OrganOx metra, enabling functional assessment and preservation for up to 24 hours. Offerings support evaluation of liver function prior to transplantation, provide more flexible transplant logistics and surgery scheduling, and support complex or lengthy surgeries by extending preservation time.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full OrganOx company profile →
OSE Immunotherapeutics
HQ: France
Website
- Description: Provider of immunotherapies in immuno-oncology, auto-immune diseases, and transplantation, with a pipeline including Tedopi (Phase 3 cancer vaccine for NSCLC resistant to checkpoint inhibitors), OSE-279 (anti-PD1), BI 765063/OSE-172 (SIRPα), OSE-127 (IL-7R; ulcerative colitis), FR104 (CD28; renal transplantation), and OSE-230 (ChemR23; chronic inflammatory diseases).
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full OSE Immunotherapeutics company profile →
Organ Transport Systems
HQ: United States
Website
- Description: Provider of portable, hypothermic, oxygenated preservation and transport technology for human organs, offering the LifeCradle HR durable perfusion unit and a complementing single-use organ chamber and fluid circuit kit.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Organ Transport Systems company profile →
SQI Diagnostics
HQ: Canada
Website
- Description: Provider of medical systems and diagnostics leveraging proprietary multiplexing, miniaturization, and automation; offerings include RALI-Dx IL-6 Severity Triage for COVID-19, rapid mobile PCR testing, Sofia SARS Antigen FIA, Sofia2 Flu+SARS Antigen FIA, QuickVue At-Home OTC COVID-19 test, and the TORdx LUNG test under development to assess donor lung health.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full SQI Diagnostics company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Vascular Perfusion Solutions
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Vascular Perfusion Solutions
2.2 - Growth funds investing in similar companies to Vascular Perfusion Solutions
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Vascular Perfusion Solutions
4.2 - Public trading comparable groups for Vascular Perfusion Solutions
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →